We are excited to announce that Biocytogen will exhibit at the AIDDD Summit from October 27th - 29th in Boston, MA. Join us in discovering how AI is changing drug development and connect with industry professionals who are turning new ideas into practice. Come meet our experts at booth #25 to learn about our innovative RenSuper Workstation™ and how it seamlessly integrates with AI-driven antibody discovery.
What is the AIDDD Summit?
The AI Drug Discovery and Development (AIDDD) Summit explores how artificial intelligence is being applied across drug research and development, from identifying targets to advancing clinical trials. The program brings together researchers, industry leaders, and technology innovators to share practical insights and discuss emerging approaches.
Event Overview
Date: October 27th - 29th, 2026
Venue: Boston Marriott Copley Place, 110 Huntington Ave, Boston, MA 02116
Booth: 25
Poster
RenSuper Workstation™: An AI-Powered, Closed-Loop In Vivo Discovery and Automation Engine for High-Efficiency Therapeutic Antibody Generation Infrastructure
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
